Avidex, a spin-off company of Oxford University develops small molecule and protein therapeutics involving T-cell receptors (TCRs) – either as drug targets or as therapeutic molecules. Avidex has two key programs (mTCR and RhuDex®) leading to novel treatments in cancer, inflammation and autoimmune diseases. Avidex’s goal is to produce novel T-cell receptor-based therapeutics in autoimmunity, cancer, virology and allergy. The products developed include RhuDex®, EsoDex®, HiDex® etc.